Status: Recruiting
Study of CAR.70-engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Advanced Renal Cell Carcinoma, Mesothelioma and Osteosarcoma
To find a recommended dose of donated NK cells that can be given with lymphodepleting chemotherapy to patients with advanced renal cell carcinoma, mesothelioma, or osteosarcoma. The effects of this therapy will also be studied.
Participants needed: 50
Trial details
Phase: Phase 1, Phase 2Age: 16-80Biological sex: AllType: InterventionalSponsor: M.D. Anderson Cancer CenterUpdated: Mar 4, 2026Locations: 1
Eligibility criteria
Patients with advanced clear cell renal cell carcinoma, osteosarcoma or mesothel... [+30]
Presence of clinically significant ongoing Grade ≥ 2 toxicity unequivocally asso... [+23]